Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise
Searching For A Functional Cure
Executive Summary
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.
You may also be interested in...
Biotech Behind Oxford’s Coronavirus Vaccine Welcomes AZ’s Big Pharma 'Muscle'
The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.
Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.
Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal
Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.